CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS | Journal of Neurology, Neurosurgery & Psychiatry

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

JNNP 100

Authors

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

PDF +
Supplementary
Material

Neuromuscular

Original research

CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Capodivento G, De Michelis C, Carpo M, et al

CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS

Journal of Neurology, Neurosurgery & Psychiatry 2021;92:303-310.